This application is a U.S. National Phase under 35 U.S.C. §371 of the International Patent Application No. PCT/AU2010/001399, filed Oct. 21, 2010, and published in English on May 5, 2011 as WO 2011/050393, which claims the benefit of Australian Patent Application No. 2009905220, filed Oct. 26, 2009, both of which are incorporated by reference in their entirety.
The present invention relates to a method and apparatus for use in analysing impedance measurements performed on a subject, and in particular to a method and apparatus for determining an indicator using a dispersion parameter, to thereby allow the indicator to be used in diagnosing the presence, absence or degree of oedema.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that the prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
One existing technique for determining biological parameters relating to a subject, such as fluid levels, involves the use of bioelectrical impedance. This involves measuring the electrical impedance of a subject's body using a series of electrodes placed on the skin surface. Changes in electrical impedance at the body's surface are used to determine parameters, such as changes in fluid levels, associated with the cardiac cycle or oedema, or other conditions which affect body habitus.
Lymphoedema is a condition characterised by excess protein and oedema in the tissues as a result of reduced lymphatic transport capacity and/or reduced tissue proteolytic capacity in the presence of a normal lymphatic load. Acquired, or secondary lymphoedema, is caused by damaged or blocked lymphatic vessels. The commonest inciting events are surgery and/or radiotherapy. However, onset of lymphoedema is unpredictable and may develop within days of its cause or at any time during a period of many years after that cause.
WO00/79255 describes a method of detection of oedema by measuring bioelectrical impedance at two different anatomical regions in the same subject at a single low frequency alternating current. The two measurements are analysed to obtain an indication of the presence of tissue oedema by comparing with data obtained from a normal population.
WO2005/122888 describes a method of detecting tissue oedema in a subject. The method includes determining a measured impedance for first and second body segments. An index indicative of a ratio of the extra-cellular to intra-cellular fluid is then calculated for each body segment, with these being used to determine an index ratio, based on the index for the first and second body segments. The index ratio can in turn be used to determine the presence, absence or degree of tissue oedema, for example by comparing the index ratio to a reference or previously determined index ratios.
WO2008/138602 describes a method for use in analysing impedance measurements performed on a subject, the method including, in a processing system determining at least one impedance value, representing the impedance of at least a segment of the subject, determining an indicator indicative of a subject parameter using the at least one impedance value and a reference and displaying a representation of the indicator.
It is an object of the present invention to substantially overcome, or at least ameliorate, one or more disadvantages of existing arrangements.
In a first broad form the present invention seeks to provide a method for use in analysing impedance measurements performed on a subject, the method including, in a processing system:
Typically the method includes, in the processing system:
Typically the first body segment is an affected body segment and the second body segment is an unaffected body segment.
Typically at least one of the body segments is a dominant limb and the other body segment is a non-dominant limb.
Typically the first body segment is a different body segment to the second body segment.
Typically the method includes, in the processing system:
Typically predicted dispersion parameter value is determined to take into account at least one of:
Typically the method includes, in the processing system, determining a predicted dispersion parameter value using at least one reference value derived from a reference normal population.
Typically the reference normal population is selected based on at least one of:
Typically the at least one reference value is determined based on a linear regression of first and second dispersion parameter values measured for the reference normal population.
Typically the method includes, in the processing system, determining the predicted dispersion parameter value using an equation of the form:
DPp=aDP2+K
Typically, for a male subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on:
Typically, for a female subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on:
Typically the method includes, in the processing system, determining the indicator using the equation:
Typically the method includes, in the processing system, determining the indicator using the equation:
Typically the scaling factor is selected so that a threshold value indicative of the presence or absence of oedema is an integer value.
Typically the method includes, in the processing system, determining the indicator based on the equation:
Ind=sf(DP2−DP1)
Typically the dispersion parameter value is indicative of the distribution of impedance measurements for the respective body segment.
Typically the dispersion parameter is based on the value of at least one of:
Typically the dispersion parameter is based on the value of:
Typically the indicator is at least one of:
Typically the method includes, in the processing system, displaying a representation of the indicator.
Typically representation of the indicator includes a linear scale including:
Typically the method includes, in the processing system, displaying a representation including an indication of a change in indicator value from at least one of a previous indicator value and a baseline indicator value.
Typically the method includes, in the processing system:
Typically the method includes, in the processing system:
Typically the method includes, in the processing system, displaying, on the representation, at least one of:
Typically the method includes in the processing system, causing one or more impedance measurements to be performed.
Typically the method includes, in the processing system:
Typically the method includes, in the processing system:
In a second broad form the present invention seeks to provide apparatus for use in analysing impedance measurements performed on a subject, the apparatus including a processing system for:
Typically the apparatus includes:
Typically the controller includes the processing system.
Typically the processing system includes the controller.
In a third broad form the present invention seeks to provide a method for use diagnosing the presence, absence or degree of oedema in a subject by using impedance measurements performed on the subject, the method including, in a processing system:
It will be appreciated that the broad forms of the invention may be used individually or in combination, and may be used for diagnosis of the presence, absence or degree of a range of conditions and illnesses, including, but not limited to oedema, lymphoedema, body composition and the like.
An example of the present invention will now be described with reference to the accompanying drawings, in which:—
An example of apparatus suitable for performing an analysis of a subject's bioelectric impedance will now be described with reference to
As shown the apparatus includes a measuring device 100 including a processing system 102, connected to one or more signal generators 117A, 117B, via respective first leads 123A, 123B, and to one or more sensors 118A, 118B, via respective second leads 125A, 125B. The connection may be via a switching device, such as a multiplexer, although this is not essential.
In use, the signal generators 117A, 117B are coupled to two first electrodes 113A, 113B, which therefore act as drive electrodes to allow signals to be applied to the subject S, whilst the one or more sensors 118A, 118B are coupled to the second electrodes 115A, 115B, which act as sense electrodes, allowing signals across the subject S to be sensed.
The signal generators 117A, 117B and the sensors 118A, 118B may be provided at any position between the processing system 102 and the electrodes 113A, 113B, 115A, 115B, and may be integrated into the measuring device 100. However, in one example, the signal generators 117A, 117B and the sensors 118A, 118B are integrated into an electrode system, or another unit provided near the subject S, with the leads 123A, 123B, 125A, 125B connecting the signal generators 117A, 117B and the sensors 118A, 118B to the processing system 102.
It will be appreciated that the above described system is a two channel device, used to perform a classical four-terminal impedance measurement, with each channel being designated by the suffixes A, B respectively. The use of a two channel device is for the purpose of example only, and multiple channel devices can alternatively be used to allow multiple body segments to be measured without requiring reattachment of electrodes. An example of such a device is described in copending patent application number WO2009059351.
An optional external interface 103 can be used to couple the measuring device 100, via wired, wireless or network connections, to one or more peripheral devices 104, such as an external database or computer system, barcode scanner, or the like. The processing system 102 will also typically include an I/O device 105, which may be of any suitable form such as a touch screen, a keypad and display, or the like.
In use, the processing system 102 is adapted to generate control signals, which cause the signal generators 117A, 117B to generate one or more alternating signals, such as voltage or current signals of an appropriate waveform, which can be applied to a subject S, via the first electrodes 113A, 113B. The sensors 118A, 118B then determine the voltage across or current through the subject S, using the second electrodes 115A, 115B and transfer appropriate signals to the processing system 102.
Accordingly, it will be appreciated that the processing system 102 may be any form of processing system which is suitable for generating appropriate control signals and at least partially interpreting the measured signals to thereby determine the subject's bioelectrical impedance, and optionally determine other information such as relative fluid levels, or the presence, absence or degree of conditions, such as oedema, lymphoedema, measures of body composition, cardiac function, or the like.
The processing system 102 may therefore be a suitably programmed computer system, such as a laptop, desktop, PDA, smart phone or the like. Alternatively the processing system 102 may be formed from specialised hardware, such as an FPGA (field programmable gate array), or a combination of a programmed computer system and specialised hardware, or the like, as will be described in more detail below.
In use, the first electrodes 113A, 113B are positioned on the subject to allow one or more signals to be injected into the subject S. The location of the first electrodes will depend on the segment of the subject S under study. Thus, for example, the first electrodes 113A, 113B can be placed on the thoracic and neck region of the subject S to allow the impedance of the chest cavity to be determined for use in cardiac function analysis. Alternatively, positioning electrodes on the wrist and ankles of a subject allows the impedance of limbs and/or the entire body to be determined, for use in oedema analysis, or the like.
Once the electrodes are positioned, one or more alternating signals are applied to the subject S, via the first leads 123A, 123B and the first electrodes 113A, 113B. The nature of the alternating signal will vary depending on the nature of the measuring device and the subsequent analysis being performed.
For example, the system can use Bioimpedance Spectroscopy (BIS) in which impedance measurements are performed at each of a number of frequencies ranging from very low frequencies (4 kHz) to higher frequencies (1000 kHz), and can use as many as 256 or more different frequencies within this range. Such measurements can be performed by applying a signal which is a superposition of plurality of frequencies simultaneously, or a number of alternating signals at different frequencies sequentially, depending on the preferred implementation. The frequency or frequency range of the applied signals may also depend on the analysis being performed.
In one example, the applied signal is generated by a voltage generator, which applies an alternating voltage to the subject S, although alternatively current signals may be applied. In one example, the voltage source is typically symmetrically arranged, with each of the signal generators 117A, 117B being independently controllable, to allow the signal voltage across the subject to be varied.
A voltage difference and/or current is measured between the second electrodes 115A, 115B. In one example, the voltage is measured differentially, meaning that each sensor 118A, 118B is used to measure the voltage at each second electrode 115A, 115B and therefore need only measure half of the voltage as compared to a single ended system.
The acquired signal and the measured signal will be a superposition of voltages generated by the human body, such as the ECG (electrocardiogram), voltages generated by the applied signal, and other signals caused by environmental electromagnetic interference. Accordingly, filtering or other suitable analysis may be employed to remove unwanted components.
The acquired signal is typically demodulated to obtain the impedance of the system at the applied frequencies. One suitable method for demodulation of superposed frequencies is to use a Fast Fourier Transform (FFT) algorithm to transform the time domain data to the frequency domain. This is typically used when the applied current signal is a superposition of applied frequencies. Another technique not requiring windowing of the measured signal is a sliding window FFT.
In the event that the applied current signals are formed from a sweep of different frequencies, then it is more typical to use a signal processing technique such as multiplying the measured signal with a reference sine wave and cosine wave derived from the signal generator, or with measured sine and cosine waves, and integrating over a whole number of cycles. This process, known variously as quadrature demodulation or synchronous detection, rejects all uncorrelated or asynchronous signals and significantly reduces random noise.
Other suitable digital and analogue demodulation techniques will be known to persons skilled in the field.
In the case of BIS, impedance or admittance measurements are determined from the signals to at each frequency by comparing the recorded voltage and the current through the subject. The demodulation algorithm can then produce amplitude and phase signals at each frequency, allowing an impedance value at each frequency to be determined.
As part of the above described process, the distance between the second electrodes 115A, 115B may be measured and recorded. Similarly, other parameters relating to the subject may be recorded, such as the height, weight, age, sex, health status, any interventions and the date and time on which they occurred. Other information, such as current medication, may also be recorded. This can then be used in performing further analysis of the impedance measurements, so as to allow determination of the presence, absence or degree of oedema, to assess body composition, or the like.
The accuracy of the measurement of impedance, can be subject to a number of external factors. These can include, for example, the effect of capacitive coupling between the subject and the surrounding environment, the leads and the subject, the electrodes, or the like, which will vary based on factors such as lead construction, lead configuration, subject position, or the like. Additionally, there are typically variations in, the impedance of the electrical connection between the electrode surface and the skin (known as the “electrode impedance”), which can depend on factors such as skin moisture levels, melatonin levels, or the like. A further source of error is the presence of inductive coupling between different electrical conductors within the leads, or between the leads themselves.
Such external factors can lead to inaccuracies in the measurement process and subsequent analysis and accordingly, it is desirable to be able to reduce the impact of external factors on the measurement process.
One form of inaccuracy that can arise is caused by the voltages across the subject being unsymmetrical, a situation referred to as an “imbalance”. Such a situation results in a significant signal voltage at the subject's body centre, which in turn results in stray currents arising from parasitic capacitances between the subject's torso and the support surface on which the subject is provided.
The presence of an imbalance, where the voltage across the subject is not symmetrical with respect to the effective centre of the subject, leads to a “common mode”, signal, which is effectively a measure of the signal at the subject. S that is unrelated to the subject's impedance.
To help reduce this effect, it is therefore desirable for signals to be applied to the subject S that they result in a symmetrical voltage about the subject's body centre. As a result, a reference voltage within the subject S, which is equal to a reference voltage of the measurement apparatus, will be close to the effective body centre of the subject, as considered relative to the electrode placement. As the measuring device reference voltage is typically ground, this results in the body centre of the subject S being as close to ground as possible, which minimises the overall signal magnitude across the subject's torso, thereby minimising stray currents.
In one example, a symmetrical voltage about the sensing electrodes cats be achieved by using a symmetrical voltage source, such as a differential bidirectional voltage drive scheme, which applies a symmetrical voltage to each of the drive electrodes 113A, 113B. However, this is not always effective if the contact impedances for the two drive electrodes 113A, 113B are unmatched, or if the impedance of the subject S varies along the length of the subject S, which is typical in a practical environment.
In one example, the apparatus overcomes this by adjusting the differential voltage drive signals applied to each of the drive electrodes 113A, 113B, to compensate for the different electrode impedances, and thereby restore the desired symmetry of the voltages across the subject S. This process is referred to herein as balancing and in one example, helps reduce the magnitude of the common mode signal, and hence reduce current losses caused by parasitic capacitances associated with the subject.
The degree of imbalance, and hence the amount of balancing required, can be determined by monitoring the signals at the sense electrodes 115A, 115B, and then using these signals to control the signal applied to the subject via the drive electrodes 113A, 113B. In particular, the degree of imbalance can be calculated by determining an additive voltage from the voltages detected at the sense electrodes 115A, 115B.
In one example process, the voltages sensed at each of the sense electrodes 115A, 115B are used to calculate a first voltage, which is achieved by combining or adding the measured voltages. Thus, the first voltage can be an additive voltage (commonly referred to as a common mode voltage or signal) which can be determined using a differential amplifier.
In this regard, a differential amplifier is typically used to combine two sensed voltage signals Va, Vb, to determine a second voltage, which in one example is a voltage differential Va−Vb across the points of interest on the subject S. The voltage differential is used in conjunction with a measurement of the current flow through the subject to derive impedance values. However, differential amplifiers typically also, provide a “common mode” signal (Va+Vb)/2, which is a measure of the common mode signal.
Whilst differential amplifiers include a common mode rejection capability, this is generally of only finite effect and typically reduces in effectiveness at higher frequencies, so a large common mode signal will produce an error signal superimposed on the differential signal.
The error caused by common mode signals can be minimised by calibration of each sensing channel. In the ideal case where both inputs of a differential amplifier are perfectly matched in gain and phase characteristics and behave linearly with signal amplitude, the common mode error will be zero. In one example, the two sensing channels of the differential amplifier are digitised before differential processing. It is therefore straightforward to apply calibration factors independently to each channel to allow the characteristics to be matched to a high degree of accuracy, thereby achieving a low common mode error.
Accordingly, by determining the common mode signal, the applied voltage signals can be adjusted, for example by adjusting the relative magnitude and/or phase of the applied signals, to thereby minimise the common mode signal and substantially eliminate any imbalance. An example of this process is described in more detail in copending patent application number WO2009059351.
An example of the operation of the apparatus in analysing impedance measurements will now be described with reference to
In one example, at step 200 the processing system 102 causes a current signal to be applied to the subject S, with the induced voltage across the subject S being measured at step 210, with signals representing the measured voltage and the applied current being returned to the processing system 102 for analysis.
When the process is being used to determine an oedema indicator, this is typically performed for at least a segment of the subject S that is suspected of being susceptible to oedema, and may also be repeated for a separate healthy segment of the subject. Thus, for example, in the case of limb oedema, this is typically performed on the affected or “at risk” limb (hereinafter generally referred to as the “affected” limb), and a limb that is deemed “not at risk” of oedema (hereinafter generally referred to as the “unaffected” limb).
It will be appreciated that the application of the current and voltage signals may be controlled by a separate processing system that is used in performing the analysis to derive an indicator, and that the use of a single processing system is for the purpose of example only.
At step 220, measured voltage and current signals are used by the processing system 102 to determine impedance values at each of a number of applied frequencies. In one example, this includes first impedance values representing the impedance of the unaffected limb and second impedance values representing the impedance of the affected limb.
At step 230, the one or more impedance values are used by the processing system 102, to determine a dispersion parameter value. In one example, first and second dispersion parameter values of affected and unaffected limbs may be determined.
The nature of the dispersion parameter can vary, but in general this represents a distribution of the impedance measurements about an ideal model.
In one example, the dispersion parameter DP can be given by or based on the value:
It should be noted that the value of Xc will be negative, due to it's position below the circle, and this can lead to the value of the dispersion parameter being negative. However, it will be appreciated that alternative formulations may also be used, such as those set out below, and accordingly, the dispersion parameter can be arranged to have either a positive or negative value, as desired:
The alternative formulations can be used to ensure that the value of the dispersion parameter increases in the event that the subject has oedema, although this is not essential and any suitable formulation may be selected.
In one particular example, the dispersion parameter DP value is given by a value α:
In this regard,
The relative magnitudes of the extracellular and intracellular components of impedance of an alternating current (AC) are frequency dependent. At zero frequency the capacitor acts as a perfect insulator and all current flows through the extracellular fluid, hence the resistance at zero frequency, R0, equals the extracellular resistance Re. At infinite frequency the capacitor acts as a perfect conductor and the current passes through the parallel resistive combination. The resistance at infinite frequency R∞ is given by:
Accordingly, the impedance of the equivalent circuit of
However, the above represents an idealised situation which does not take into account the fact that the cell membrane is an imperfect capacitor. Taking this into account leads to a modified model in which:
An example of the typical multi-frequency impedance response is shown in
The α parameter is related to the depression of the Cole plot below the zero reactance axis. The value of α is indicative of the deviation from the ideal Cole equation (4) and is closely related to the spectral width of the distribution of relaxation times. This dispersion may be due to molecular interactions, cellular interactions, anisotropy and cell size as described in Grimnes, S. and O. G. Martinsen (2000). Bioimpedance and Bioelectricity Basics, Academic Press.
As described above, the value of the impedance parameter R0 is closely related to extra-cellular fluid levels while the impedance parameter value R∞ is closely related to the total body fluid levels. Accordingly, (R0−R∞) is closely related to the intra-cellular fluid levels.
The reactance Xc is the reactance X at the centre of the circle which is a direct measure of the depression of the circular locus below the axis. It is closely related to the reactance at the characteristic frequency by the subtraction from the radius of the locus. At the characteristic frequency, the ratio of the current flow through the intra and extra cellular fluids is determined as a function of the ratio of the intra to extra cellular resistance, so that it is independent of the capacitance of the cell membrane. Accordingly, the reactance at the characteristic frequency can be used more accurately as an indicator of extra-cellular fluid levels. Since the reactance at the centre of the circle is directly related to the characteristic reactance, this value is also related to the intra and extra cellular fluid.
Accordingly, the dispersion parameter is not only related to a ratio of extra-cellular to intra-cellular fluid levels, but also takes into account deviation from an idealised equivalent circuit reflecting the distribution of relaxation times within the subject and so encompasses changes in cell structure. In contrast, if a direct ratio of intra-cellular to extra-cellular fluid is used as an index I this is typically calculated as shown in equation (6) below and therefore does not account for such deviations to the same extent.
As lymphoedema is characterised by the accumulation of extra-cellular fluid, the dispersion parameter is different between a healthy and oedema affected population, with the difference being more readily quantifiable than if a direct ratio of intra-cellular to extra-cellular, given by equation (6) is used.
An example of the propagation of errors in the calculation of a dispersion parameter alpha and a ratio of intra-cellular to extra-cellular fluid will now be described. In order to determine the propagation of errors, it is necessary to take into account typical measurement errors in different frequency ranges for a typical measurement device, and these are shown in Table 1 below.
In this instance, the relative error in the index I from equation (6) is given by:
Similarly the relative error in the indicator Ind from equation (1) is given by:
Given the typical errors specifications for the measuring devices outlined in Table 1 above, and taking example leg impedance measurements, this leads to example impedance parameter values of:
R0=372Ω±1%
R∞=25Ω±2%
XC=−28Ω±1%
Accordingly, this leads to errors of:
This demonstrates that the alpha parameter can be determined more accurately and should therefore be more sensitive to fluid level changes within the subject, and hence the presence absence or degree of oedema.
At step 240, the dispersion parameter can be used to determine an indicator. In one example; the indicator provides information relating to the subject, such as an indication of fluid levels within the subject. In one example, the indicator is in the form of a numerical value that depends on a reference, and which can be used to determine the presence, absence or degree of a condition, such as oedema.
In one particular example, the reference is at least partially based on the dispersion parameter of an unaffected body segment. In particular, if the affected body segment does not in fact have oedema, then the dispersion parameter will be similar to the dispersion parameter for the unaffected body segment, thereby minimising a difference between first and second dispersion parameters. In contrast if the affected body segment has oedema the fluid levels will differ to the fluid levels in the unaffected body segment, meaning that the difference between the first and second dispersion parameters increases. As a result, the magnitude of the difference in first and second dispersion parameters between first and second body segments can be indicative of the presence, absence or degree of oedema. Accordingly, by comparing the difference between the dispersion parameters of affected and unaffected body segments to a threshold amount, then this can therefore be used to determine the presence, absence or degree of oedema.
In one example, the difference is scaled by a scaling factor so that the indicator and the threshold can be a memorable value, such as an integer value, or the like. This can be achieved by calculating an indicator as follows:
Ind=sf(DP2−DP1) (7)
However, a population study of healthy subjects has found inherent differences in fluid levels between different body segments, such as limbs, even in unaffected individuals. This can include slight differences in dispersion parameters due to limb dominance in limbs as well as differences arising if the unaffected and affected limbs are of different limb types, such as arms and legs. For example, the dispersion parameter for a subject's leg will typically differ to that of the subject's arm, even in the absence of oedema in both limbs.
Accordingly, when calculating the reference it is typical to determine a predicted dispersion parameter value for the affected limb based on the second dispersion parameter value determined for the unaffected limb. This is usually achieved using at least one reference value derived from a reference normal population, allowing the natural variations between limbs due to gender, limb dominance and different limb types to be accommodated.
In one particular example, the predicted dispersion parameter value is calculated based on parameters derived by performing a linear regression of first and second dispersion parameter values measured for a reference population. The predicted dispersion parameter value can then be determined using an equation of the form:
DPp=aDP2+K (8)
In one example, for a male subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on a value of a in the range 0.15 to 0.022, and a value of K in the range 0.62 to 0.72. For a female subject, the predicted value for a leg segment based on second dispersion parameters for an arm segment is based on a value of a in the range 0.44 to 0.41, and a value of K in the range 0.43 to 0.46.
When a predicted dispersion parameter value is used, the indicator can be determined using the equation:
It should be noted that in the event that measurements are made for an affected body segment only, then the predicted dispersion parameter value could alternatively be based on a mean value obtained from a reference population, leading to an indicator of the form:
Accordingly, it will be appreciated that the above described dispersion parameter can be used in diagnosing the presence, absence or degree of oedema. Furthermore, in contrast to prior art techniques, a dispersion parameter tends to provide more reliable results, as will be discussed in more detail below.
In the above examples, it will be appreciated that the order of the dispersion parameters could be reversed, so that for example in equation (9) the predicted value could be subtracted from the measured value and this will depend on the nature of the dispersion parameter used, so for example whether the dispersion parameter is based on equations (1), (1A), (1B), (1C), (2), or variations thereof. In general the order used will be selected so that the indicator Ind increases in magnitude as the level of oedema increases, however this is not essential and any suitable arrangement may be used.
An example of the process for performing impedance measurements to determine an indicator for limb oedema will now be described in more detail with reference to
In this example, at step 400 subject details are determined and provided to the processing system 102. The subject details will typically include information such as limb dominance, details of any medical interventions, as well as information regarding the subject such as the subject's age, weight, height, sex, ethnicity or the like. The subject details can be used in selecting a suitable reference normal population, as well as for generating reports, as will be described in more detail below.
It will be appreciated that the subject details may be supplied to the processing system 102 via appropriate input means, such as the I/O device 105. Thus, each time a subject measurement is performed this information can be input into the measuring device 100.
However, more typically the information is input a single time and stored in an appropriate database, or the like, which may be connected as a peripheral device 104 via the external interface 103. The database can include subject data representing the subject details, together with information regarding previous oedema indicators, baseline measurements or impedance measurements recorded for the subject.
In this instance, when the operator is required to provide subject details, the operator can use the processing system 102 to select a search database option allowing the subject details to be retrieved. This is typically performed on the basis of a subject identifier, such as a unique number assigned to the individual upon admission to a medical institution, or may alternatively be performed on the basis of name or the like. Such a database is generally in the form of an HL7 compliant remote database, although any suitable database may be used.
In one example, the subject can be provided with a wristband or other device, which includes coded data indicative of the subject identifier. In this case, the measuring device 100 can be coupled to a peripheral device 104, such as a barcode or RFID (Radio Frequency Identification) reader allowing the subject identifier to be detected and provided to the processing system 102, which in turn allows the subject details to be retrieved from the database. The processing system 102 can then display an indication of the subject details retrieved from the database, allowing the operator to review these and confirm their accuracy before proceeding further.
At step 410 the affected limb, or “at risk” limb, is determined. This may be achieved in any one of a number of ways depending on the preferred implementation. Thus, for example, the affected limb can be indicated through the use of appropriate input means, such as the I/O device 105. Alternatively this information can be derived directly from the subject details, which, may include an indication of the affected limb, or details of any medical interventions performed, which are in turn indicative of the affected limb.
At step 420 an operator positions the electrodes on the subject S, and connects the leads 123, 124, 125, 126, to allow the impedance measurements to be performed. The general arrangement is to provide electrodes on the hand at the base of the knuckles and between the bony protuberances of the wrist, as shown in
It will be appreciated that this configuration uses the theory of equal potentials, allowing the electrode positions to provide reproducible results for impedance measurements. For example when current is injected between electrodes 113A and 113B in
This is advantageous as it greatly reduces the variations in measurements caused by poor placement of the electrodes by the operator. It also greatly reduces the number of electrodes required to perform segmental body measurements, as well as allowing the limited connections shown to be used to measure each limb separately.
However, it will be appreciated that any suitable electrode and lead arrangement may be used.
At step 430 the impedance of the affected and unaffected limbs are measured. This is achieved by applying one or more current signals to the subject and then measuring the corresponding voltages induced across the subject S. It will be appreciated that in practice the signal generators 117A, 117B, and the sensors 118A, 118B, return signals to the processing system 102 indicative of the applied current and the measured voltage, allowing impedances to be determined.
Following at step 440 a dispersion parameter DP for each of the limbs is determined using equations (1) or (2) above.
At step 450 a reference is selected. The reference is typically derived from equivalent measurements made on a normal population (subject's not suffering from oedema) that is relevant to the subject under study. Thus, the normal population is typically selected taking into account factors such as medical interventions performed, ethnicity, sex, height, weight, limb dominance, the affected limb, or the like.
Therefore if the test subject is female having bilateral lymphoedema of the dominant leg then the normalised data drawn from the normal population database will be calculated from the dominant leg impedance ratio measurements from female subjects that are present in the normal population database.
Accordingly, at this stage the processing system 102 typically accesses reference populations stored in the database, or the like. This may be performed automatically by the processing system 102 using the subject details. Thus for example, the database may include a look-up table that specifies the normal population that should be used given a particular set of subject details. Alternatively selection may be achieved in accordance with predetermined rules that can be derived using heuristic algorithms based on selections made by medically qualified operators during previous procedures. Alternatively, this may be achieved under control of the operator, depending on the preferred implementation.
It will be appreciated by persons skilled in the art that operators may have their own reference stored locally. However, in the event that suitable references are not available, the processing system 102 can be used to retrieve a reference from a central repository, for example via an appropriate server arrangement. In one example, this may be performed on a pay per use basis.
Alternatively, in the event that a suitable reference is not available predetermined standard reference values may be used, as described above. However it will be appreciated that different values can be used as appropriate and that these values are for illustration only.
At step 460 a predicted dispersion parameter value for the affected body segment is determined using the second dispersion value derived for the unaffected body segment and the reference values, as described above with respect to equation (8).
Following this an indicator can be determined using equation (9) at step 470. As described above, this is typically achieved by scaling the difference between the predicted and measured dispersion parameter values for the affected arm. This is performed so that the value of the indicator at a threshold indicative of the presence of oedema corresponds to a memorable value. In one example, the scaling factor is set so that an indicator value of greater than “10” is indicative of oedema, whilst a value of below “10” is used to indicate an absence of oedema.
Representations of the indicator can then optionally be displayed at step 480. Examples of such representations for oedema indicators will now be described with reference to
In these examples, the representation is in the form of a linear indicator 600, having an associated scale 601 and a pointer 602. The position of the pointer 602 relative to the scale 601 is indicative of the subject parameter, which in this example is based on an impedance ratio representing a ratio of fluid levels determined for healthy and affected limbs of the subject.
In the example of
In use the lower and upper thresholds 611, 612 define a normal range 620, an investigation range 621, and an oedema range 622. The ranges can be indicated through the use of background colours on the linear indicator, so that for example, the normal range 620 is shaded green, whilst the investigation range 621 is unshaded, and the oedema range 622 is shaded red. This allows an operator to rapidly evaluate the positioning of the pointer 602 within the ranges, allowing for fast and accurate diagnosis of oedema based on the indicated fluid level information.
Thus, in the example of
In this example, the linear indicator extends up to a value of “20” as this is able to accommodate the determined value of 16.6. However, it will be appreciated that the linear indicator can be extended to any value required to accommodate the determined indicator value. To ensure that the linear scale remains clear, particularly if an extreme indicator value is to be displayed, the linear indicator 600 may include discontinuities, allowing the scale to be extended to higher values. An example of this is shown in
Whilst a linear indicator 600 is preferred as this easily demonstrates to the operator the potential degree of severity of any oedema, this is not essential, and alternatively the scale may be modified, particularly if an outlier indicator value is determined. Thus, for example, the linear indicator could include logarithmic scaling, or the like, over all or part of its length, to allow the determined indicator value to be displayed.
In the event that the indicator value is between “−10” and “+10”, this indicates that the subject S is within the normal range 620 and that therefore they do not have oedema. Finally, in the event that the indicator value is below “−10”, then the subject S is within the investigation range 621, indicating that the measurements need to be investigated further. In particular, it is extremely unlikely that, the affected limb could have an impedance value significantly smaller than that of the unaffected limb, and accordingly, this indicates that in all likelihood there has been an error in the measurement, such as incorrect designation of the affected limb, or incorrect connection of electrodes.
In the example of
As a result an oedema indicator value of above “10” is still indicative of oedema, but may be a less reliable indicator than if the reference is available. To take this into account, the thresholds 611, 612, and hence the specific ranges 620, 621, 622, are excluded from the representation, highlighting to the operator that the scaled subject parameter value is indicative but not definitive of the subject's oedema status.
A survey of the normal population was conducted using an Impedimed SFB7 device to determine the “normal” values for the Cole parameters. 65 self diagnosed healthy females and 29, self diagnosed healthy males participated in a trial with the population demographics being shown in Table 2. The average and standard deviation of the Cole parameters for each limb was determined for both the dominant and non dominant limbs.
Of the single Cole parameters, a is the parameter that has the lowest variation for all limbs within a normal population (COV=1-3%), thereby indicating that this is generally a more consistent parameter for healthy individuals.
The variation of some combinations of the Cole parameters was also investigated. The parameters with the lowest coefficient of variation in a control population were R0/R∞, R0/Xc. Ri/Re has a large coefficient of variation (10-15%) which suggests that this would make it difficult to use this impedance ratio to successfully distinguish between inherent variations within a subject, and variations induced by the presence of oedema or lymphoedema.
The normal arm to leg ratio calculated from the reference data for the same Cole parameters again results in the parameters having the lowest variation (<5%) being α, R0/R∞ and R0/Xc.
To evaluate a bilateral approach, leg data from leg lymphoedema sufferers was obtained. Data was collected during a clinical trial in which 30 volunteers were invited to participate. Each subject was classified into the Control, Bilateral Lymphoedema or Unilateral Lymphoedema group based on provided medical history. Subjects were required to lie in a supine position while electrodes were attached to the hands and feet using standard placement markers. Three swept frequency bioimpedance measurements of each limb were recorded.
The population demographics are shown in Table 3 for the subjects who met eligibility criteria. The mean subject age was significantly higher than for the normal data previously collected in a healthy population. The mean heights for both trials are comparable and the mean weight for the control subjects was comparable to the normal data collected previously. However the unilateral and bilateral subjects recorded higher weights. This is to be expected as the amount of fluid in a leg affected by lymphoedema will contribute to the weight.
A review of the COV in Table 2 suggests that other parameters other than Ri/Re are more stable within a normal population. These are the R0/R∞, Ro/Xc and α parameters.
An indicator was derived for each single limb from the R0/R∞, Ro/Xc and α parameters. The results for an indicator calculated based on α are shown in table 46, using a reference from a standard population. The indicator is calculated for each limb independently using a reference value for a obtain from the reference normal population, as shown in equation (10).
In this example, the indicator values are negative as the reference dispersion parameter was subtracted from the measured value (the reverse situation to that shown in equation (10)) and as a decreases with an increase in lymphoedema. In this example, the scaling factor is selected so that −10 is an indication of lymphoedema.
Table 5 shows the specificity and sensitivity of the dispersion parameter α in being indicative of the presence of lymphodema. These results are greatly improved compared to using an Ri/Re, ratio for each limb. It should be noted that the sensitivity of the arms cannot be calculated as no affected arms were measured.
The biggest concern for this approach is the high indicator value recorded for three of the arms of the subjects. It would be expected that the indicator calculated for these unaffected arms would be within the normal range. In addition, the positive assessment of lymphoedema in some of the unaffected legs of the unilateral subjects may not be a false positive, but rather a sign that the lymphoedema is present in both legs.
The results highlight the ability to assess the presence of lymphoedema from the measurement of a single affected limb, meaning that this allows a technique to be implemented that requires only a single measurement of the affected limb.
Arm to leg ratios that resulted in a low coefficient of variation were again R0R∞, R0/Xc and α. From these, an indicator was calculated for the dominant and non dominant leg from the arm to leg ratios, similar to equation (7). The parameter that showed the greatest effectiveness is the ratio of arm to leg for the dispersion parameter α. Table 6 shows the specificity and sensitivity using this method is still low.
The above results suggest that perhaps the relationship between the arm and leg is not a one to one relationship. The ratio of affected to unaffected limb approach works well with unilateral lymphoedema as the affected limb is compared to an equivalent but contra-lateral limb. The ratio of unaffected limb to affected limb is very close to 1. This is the equivalent of assuming a linear relationship between the limbs without a constant offset. That is y=mx+c without the intercept c and where m is the normal ratio.
In essence this uses the healthy limb to predict what we would expect the affected limb to be if it were also unaffected. The deviation of the expected result from the measured result is then compared to the normal variation within a healthy population to assess the presence of lymphoedema. In the case of comparing an arm to a leg, there are a number or differences in geometry and structure such as cross sectional area and length. This would indicate an additional offset between the two measurements and suggest that the relationship between arms and legs may be linear. These concepts are shown graphically in
An example of the variation of a normal leg α with normal arm α is shown for dominant arms and legs for healthy females in
Regression analysis was performed on the healthy male and female, dominant and non dominant limb data to determine the line of best fit for the chosen parameters. The female normal data shows a stronger association (R>0.5) than the male data (R=0.2) for all parameters.
The resulting linear equations used to predict leg data from arm data are grouped by gender and dominance. The best performing parameter is α. The equations are shown below.
Female Dominant: αleg=0.4416αarm+0.4379,SE=0.0136
Female Non Dominant: αleg=0.4176αarm+0.4581,SE=0.0136
Male Dominant: αleg=0.1572αarm+0.6227,SE=0.0113
Male Non Dominant: αleg=0.0217αarm+0.7145,SE=0.0109
These regression equations were then used to predict the expected leg α from the measured arm α, using equation (8) above. Next the predicted leg α was subtracted from the measured leg α. This difference between the actual and predicted result was then compared to the standard error for a normal population. An indicator value was calculated according to equation (9).
Example results for leg α predicted from arm measurements are shown in Table 7.
These results highlight that the use of the dispersion parameter α together with the prediction of an expected value for the affected limb based on measurements for the unaffected limb provide a high reliability of identification of lymphoedema as highlighted by sensitivity and specificity measures shown in Table 8. Of all methods presented, the results demonstrate the highest specificity and sensitivity.
It should be noted that Bilateral subject UB500-01-03 did not record an indicator of greater than 10. This can be explained as the subject had a very mild case of lymphoedema affecting only the upper most part of the thigh. It is expected that the contribution of the lymphoedema to the measured bioimpedance was not significant to be greatly altered from the normal state. However it will be noticed that in both legs an indicator score was, obtained that was greater than 8.
The remaining unilateral subjects whose unaffected leg produced an indicator of greater than 10, are potentially showing signs of developing lymphoedema in the other leg.
Accordingly, this highlights that using a dispersion parameter has been shown to produce the best results in predicting the presence of lymphoedema.
Persons skilled in the art will appreciate that numerous variations and modifications will become apparent. All such variations and modifications which become apparent to persons skilled in the art, should be considered to fall within the spirit and scope that the invention broadly appearing before described.
Thus, for example, it will be appreciated that features from different examples above may be used interchangeably where appropriate. Furthermore, whilst the above examples have focussed on a subject such as a human, it will be appreciated that the measuring device and techniques described above can be used with any animal, including but not limited to, primates, livestock, performance animals, such race horses, or the like.
The above described processes can be used for determining the health status of an individual, including the body composition of the individual, or diagnosing the presence, absence or degree of a range of conditions and illnesses, including, but not limited to oedema, lymphoedema, or the like. It will be appreciated from this that whilst the above examples use the term oedema indicator, this is for the purpose of example only and is not intended to be limiting. Accordingly, the oedema indicator can be referred to more generally as an indicator when used in analysing impedance measurements with respect to more general health status information such as body composition, or the like.
Number | Date | Country | Kind |
---|---|---|---|
2009905220 | Oct 2009 | AU | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/AU2010/001399 | 10/21/2010 | WO | 00 | 8/3/2012 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2011/050393 | 5/5/2011 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3316896 | Thomasset | May 1967 | A |
3851641 | Toole et al. | Dec 1974 | A |
3866600 | Rey | Feb 1975 | A |
3868165 | Gonser | Feb 1975 | A |
3871359 | Pacela | Mar 1975 | A |
4008712 | Nyboer | Feb 1977 | A |
4034854 | Bevilacqua | Jul 1977 | A |
4082087 | Howson | Apr 1978 | A |
4121575 | Mills et al. | Oct 1978 | A |
4144878 | Wheeler | Mar 1979 | A |
RE30101 | Kubicek et al. | Sep 1979 | E |
4169463 | Piquard | Oct 1979 | A |
4184486 | Papa | Jan 1980 | A |
4233987 | Feingold | Nov 1980 | A |
4291708 | Frei et al. | Sep 1981 | A |
4314563 | Wheeler | Feb 1982 | A |
4353372 | Ayer | Oct 1982 | A |
4365634 | Bare et al. | Dec 1982 | A |
4407288 | Langer et al. | Oct 1983 | A |
4407300 | Davis | Oct 1983 | A |
4450527 | Sramek | May 1984 | A |
4458694 | Sollish et al. | Jul 1984 | A |
4486835 | Bai et al. | Dec 1984 | A |
4537203 | Machida | Aug 1985 | A |
4539640 | Fry et al. | Sep 1985 | A |
4557271 | Stoller et al. | Dec 1985 | A |
4583549 | Manoli | Apr 1986 | A |
4602338 | Cook | Jul 1986 | A |
4617939 | Brown et al. | Oct 1986 | A |
4638807 | Ryder | Jan 1987 | A |
4646754 | Seale | Mar 1987 | A |
4686477 | Givens et al. | Aug 1987 | A |
4688580 | Ko et al. | Aug 1987 | A |
4763660 | Kroll et al. | Aug 1988 | A |
4793362 | Tedner | Dec 1988 | A |
4832608 | Kroll | May 1989 | A |
4836214 | Sramek | Jun 1989 | A |
4890630 | Kroll et al. | Jan 1990 | A |
4895163 | Libke et al. | Jan 1990 | A |
4899758 | Finkelstein et al. | Feb 1990 | A |
4905705 | Kizakevich et al. | Mar 1990 | A |
4911175 | Shizgal | Mar 1990 | A |
4922911 | Wada et al. | May 1990 | A |
4924875 | Chamoun | May 1990 | A |
4942880 | Sloväk | Jul 1990 | A |
4951682 | Petre | Aug 1990 | A |
4981141 | Segalowitz | Jan 1991 | A |
5020541 | Marriott | Jun 1991 | A |
5025784 | Shao et al. | Jun 1991 | A |
5063937 | Ezenwa et al. | Nov 1991 | A |
5078134 | Heilman et al. | Jan 1992 | A |
5086781 | Bookspan | Feb 1992 | A |
5101828 | Welkowitz et al. | Apr 1992 | A |
5143079 | Frei et al. | Sep 1992 | A |
5184624 | Brown et al. | Feb 1993 | A |
5197479 | Hubelbank et al. | Mar 1993 | A |
5199432 | Quedens et al. | Apr 1993 | A |
5233982 | Kohl | Aug 1993 | A |
5246008 | Mueller | Sep 1993 | A |
5272624 | Gisser et al. | Dec 1993 | A |
5280429 | Withers | Jan 1994 | A |
5282840 | Hudrlik | Feb 1994 | A |
5284142 | Goble et al. | Feb 1994 | A |
5305192 | Bonte et al. | Apr 1994 | A |
5309917 | Wang et al. | May 1994 | A |
5311878 | Brown et al. | May 1994 | A |
5335667 | Cha et al. | Aug 1994 | A |
5351697 | Cheney et al. | Oct 1994 | A |
5353802 | Ollmar | Oct 1994 | A |
5372141 | Gallup et al. | Dec 1994 | A |
5381333 | Isaacson et al. | Jan 1995 | A |
5390110 | Cheney et al. | Feb 1995 | A |
5415164 | Faupel e | May 1995 | A |
5421345 | Lekholm et al. | Jun 1995 | A |
5423326 | Wang et al. | Jun 1995 | A |
5427113 | Hiroshi et al. | Jun 1995 | A |
5449000 | Libke et al. | Sep 1995 | A |
5454377 | Dzwonczyk et al. | Oct 1995 | A |
5465730 | Zadehkoochak et al. | Nov 1995 | A |
5469859 | Tsoglin et al. | Nov 1995 | A |
5503157 | Sramek | Apr 1996 | A |
5505209 | Reining | Apr 1996 | A |
5511553 | Segalowitz | Apr 1996 | A |
5526808 | Kaminsky | Jun 1996 | A |
5529072 | Sramek | Jun 1996 | A |
5544662 | Saulnier et al. | Aug 1996 | A |
5557242 | Wetherell | Sep 1996 | A |
5562607 | Gyory | Oct 1996 | A |
5575929 | Yu et al. | Nov 1996 | A |
5588429 | Isaacson et al. | Dec 1996 | A |
5611351 | Sato et al. | Mar 1997 | A |
5615689 | Kotler | Apr 1997 | A |
5626146 | Barber et al. | May 1997 | A |
5704355 | Bridges | Jan 1998 | A |
5730136 | Laufer et al. | Mar 1998 | A |
5732710 | Rabinovich et al. | Mar 1998 | A |
5735284 | Tsoglin et al. | Apr 1998 | A |
5746214 | Brown et al. | May 1998 | A |
5759159 | Masreliez | Jun 1998 | A |
5788643 | Feldman | Aug 1998 | A |
5800350 | Coppleson et al. | Sep 1998 | A |
5807251 | Wang et al. | Sep 1998 | A |
5807270 | Williams | Sep 1998 | A |
5807272 | Kun et al. | Sep 1998 | A |
5810742 | Pearlman | Sep 1998 | A |
5876353 | Riff | Mar 1999 | A |
5919142 | Boone et al. | Jul 1999 | A |
5947910 | Zimmet | Sep 1999 | A |
5957861 | Combs et al. | Sep 1999 | A |
5964703 | Goodman et al. | Oct 1999 | A |
5994956 | Concorso | Nov 1999 | A |
6006125 | Kelly et al. | Dec 1999 | A |
6011992 | Hubbard et al. | Jan 2000 | A |
6015389 | Brown | Jan 2000 | A |
6018677 | Vidrine et al. | Jan 2000 | A |
6101413 | Olson et al. | Aug 2000 | A |
6115626 | Whayne et al. | Sep 2000 | A |
6122544 | Organ | Sep 2000 | A |
6125297 | Siconolfi | Sep 2000 | A |
6129666 | DeLuca et al. | Oct 2000 | A |
6142949 | Ubby | Nov 2000 | A |
6151523 | Ferrer et al. | Nov 2000 | A |
6167300 | Cherepenin et al. | Dec 2000 | A |
6173003 | Whikehart et al. | Jan 2001 | B1 |
6228022 | Friesem et al. | May 2001 | B1 |
6228033 | Koobi | May 2001 | B1 |
6233473 | Shepherd et al. | May 2001 | B1 |
6236886 | Cherepenin et al. | May 2001 | B1 |
6248083 | Smith et al. | Jun 2001 | B1 |
6253100 | Zhdanov | Jun 2001 | B1 |
6256532 | Cha | Jul 2001 | B1 |
6280396 | Clark | Aug 2001 | B1 |
6292690 | Petrucelli et al. | Sep 2001 | B1 |
6308097 | Pearlman | Oct 2001 | B1 |
6339722 | Heethaar et al. | Jan 2002 | B1 |
6354996 | Drinan et al. | Mar 2002 | B1 |
6376023 | Mori | Apr 2002 | B1 |
6432045 | Lemperle et al. | Aug 2002 | B2 |
6459930 | Takehara et al. | Oct 2002 | B1 |
6469732 | Chang et al. | Oct 2002 | B1 |
6472888 | Oguma et al. | Oct 2002 | B2 |
6496725 | Kamada et al. | Dec 2002 | B2 |
6497659 | Rafert | Dec 2002 | B1 |
6501984 | Church et al. | Dec 2002 | B1 |
6511438 | Bernstein et al. | Jan 2003 | B2 |
6512949 | Combs et al. | Jan 2003 | B1 |
6516218 | Cheng et al. | Feb 2003 | B1 |
6522910 | Gregory | Feb 2003 | B1 |
6532384 | Fukuda | Mar 2003 | B1 |
6551252 | Sackner et al. | Apr 2003 | B2 |
6556001 | Wiegand et al. | Apr 2003 | B1 |
6560480 | Nachaliel et al. | May 2003 | B1 |
6561986 | Baura et al. | May 2003 | B2 |
6564079 | Cory et al. | May 2003 | B1 |
6569160 | Goldin et al. | May 2003 | B1 |
6584348 | Glukhovsky | Jun 2003 | B2 |
6602201 | Hepp et al. | Aug 2003 | B1 |
6615077 | Zhu et al. | Sep 2003 | B1 |
6618616 | Iijima et al. | Sep 2003 | B2 |
6623312 | Merry et al. | Sep 2003 | B2 |
6625487 | Herleikson | Sep 2003 | B2 |
6631292 | Liedtk | Oct 2003 | B1 |
6633777 | Szopinski | Oct 2003 | B2 |
6636754 | Baura et al. | Oct 2003 | B1 |
6643543 | Takehara et al. | Nov 2003 | B2 |
6658296 | Wong et al. | Dec 2003 | B1 |
6714813 | Ishigooka et al. | Mar 2004 | B2 |
6714814 | Yamada et al. | Mar 2004 | B2 |
6723049 | Skladnev et al. | Apr 2004 | B2 |
6724200 | Fukuda | Apr 2004 | B2 |
6725089 | Komatsu et al. | Apr 2004 | B2 |
6760617 | Ward et al. | Jul 2004 | B2 |
6763263 | Gregory et al. | Jul 2004 | B2 |
6768921 | Organ et al. | Jul 2004 | B2 |
6788966 | Kenan et al. | Sep 2004 | B2 |
6790178 | Mault et al. | Sep 2004 | B1 |
6807443 | Keren | Oct 2004 | B2 |
6829501 | Nielsen et al. | Dec 2004 | B2 |
6829503 | Alt | Dec 2004 | B2 |
6840907 | Brydon | Jan 2005 | B1 |
6845264 | Skladnev et al. | Jan 2005 | B1 |
6870109 | Villarreal | Mar 2005 | B1 |
6875176 | Mourad et al. | Apr 2005 | B2 |
6906533 | Yoshida | Jun 2005 | B1 |
6922586 | Davies | Jul 2005 | B2 |
6936012 | Wells | Aug 2005 | B2 |
6940286 | Wang et al. | Sep 2005 | B2 |
RE38879 | Goodman et al. | Nov 2005 | E |
6980852 | Jersey-Willuhn et al. | Dec 2005 | B2 |
6980853 | Miyoshi et al. | Dec 2005 | B2 |
7065399 | Nakada | Jun 2006 | B2 |
7079889 | Nakada | Jul 2006 | B2 |
7096061 | Arad | Aug 2006 | B2 |
7122012 | Bouton et al. | Oct 2006 | B2 |
7130680 | Kodama et al. | Oct 2006 | B2 |
7132611 | Gregaard et al. | Nov 2006 | B2 |
7148701 | Park et al. | Dec 2006 | B2 |
7149573 | Wang | Dec 2006 | B2 |
7169107 | Jersey-Willuhn et al. | Jan 2007 | B2 |
7184820 | Jersey-Willuhn et al. | Feb 2007 | B2 |
7184821 | Belalcazar et al. | Feb 2007 | B2 |
7186220 | Stahmann et al. | Mar 2007 | B2 |
7206630 | Tarler | Apr 2007 | B1 |
7212852 | Smith et al. | May 2007 | B2 |
7233823 | Simond et al. | Jun 2007 | B2 |
7251524 | Hepp et al. | Jul 2007 | B1 |
7288943 | Matthiessen et al. | Oct 2007 | B2 |
D557809 | Neverov et al. | Dec 2007 | S |
7313435 | Nakada et al. | Dec 2007 | B2 |
7317161 | Fukuda | Jan 2008 | B2 |
7336992 | Shiokawa | Feb 2008 | B2 |
7440796 | Woo et al. | Oct 2008 | B2 |
7457660 | Smith et al. | Nov 2008 | B2 |
7477937 | Iijima et al. | Jan 2009 | B2 |
7496450 | Ortiz Alemn | Feb 2009 | B2 |
7499745 | Littrup et al. | Mar 2009 | B2 |
D603051 | Causevic et al. | Oct 2009 | S |
7603158 | Nachman | Oct 2009 | B2 |
7603171 | Eror et al. | Oct 2009 | B2 |
7628761 | Gozani et al. | Dec 2009 | B2 |
7638341 | Rubinsky et al. | Dec 2009 | B2 |
7657292 | Baker et al. | Feb 2010 | B2 |
7660617 | Davis | Feb 2010 | B2 |
7706872 | Min et al. | Apr 2010 | B2 |
7711418 | Garber et al. | May 2010 | B2 |
7729756 | Mertelmeier et al. | Jun 2010 | B2 |
7733224 | Tran | Jun 2010 | B2 |
7749013 | Sato et al. | Jul 2010 | B2 |
7860557 | Istvan et al. | Dec 2010 | B2 |
7917202 | Chamney et al. | Mar 2011 | B2 |
D641886 | Causevic et al. | Jul 2011 | S |
7983853 | Wang et al. | Jul 2011 | B2 |
D647208 | Rothman et al. | Oct 2011 | S |
8055335 | Stylos | Nov 2011 | B2 |
8068906 | Chetham | Nov 2011 | B2 |
8172762 | Robertson | May 2012 | B2 |
8233617 | Johnson et al. | Jul 2012 | B2 |
8233974 | Ward et al. | Jul 2012 | B2 |
D669186 | Gozani | Oct 2012 | S |
D669187 | Gozani | Oct 2012 | S |
8285356 | Bly et al. | Oct 2012 | B2 |
D674096 | Gaw et al. | Jan 2013 | S |
8467865 | Gregory et al. | Jun 2013 | B2 |
8744564 | Ward et al. | Jun 2014 | B2 |
D718458 | Vosch et al. | Nov 2014 | S |
D719660 | Vosch et al. | Dec 2014 | S |
D728801 | Machon et al. | May 2015 | S |
20010007056 | Linder et al. | Jul 2001 | A1 |
20010007924 | Kamada et al. | Jul 2001 | A1 |
20010020138 | Ishigooka et al. | Sep 2001 | A1 |
20010021799 | Ohlsson et al. | Sep 2001 | A1 |
20010025139 | Pearlman | Sep 2001 | A1 |
20010051774 | Littrup et al. | Dec 2001 | A1 |
20020020138 | Walker et al. | Feb 2002 | A1 |
20020022773 | Drinan et al. | Feb 2002 | A1 |
20020022787 | Takehara et al. | Feb 2002 | A1 |
20020035334 | Meij et al. | Mar 2002 | A1 |
20020072686 | Hoey et al. | Jun 2002 | A1 |
20020079910 | Fukuda | Jun 2002 | A1 |
20020093992 | Plangger | Jul 2002 | A1 |
20020106681 | Wexler et al. | Aug 2002 | A1 |
20020109621 | Khair et al. | Aug 2002 | A1 |
20020111559 | Kurata et al. | Aug 2002 | A1 |
20020123694 | Organ et al. | Sep 2002 | A1 |
20020138019 | Wexler et al. | Sep 2002 | A1 |
20020161311 | Ward et al. | Oct 2002 | A1 |
20020193689 | Bernstein et al. | Dec 2002 | A1 |
20020194419 | Rajput et al. | Dec 2002 | A1 |
20030004403 | Drinan et al. | Jan 2003 | A1 |
20030009111 | Cory et al. | Jan 2003 | A1 |
20030023184 | Pitts-Crick et al. | Jan 2003 | A1 |
20030028221 | Zhu et al. | Feb 2003 | A1 |
20030036713 | Bouton et al. | Feb 2003 | A1 |
20030050570 | Kodama et al. | Mar 2003 | A1 |
20030073916 | Yonce | Apr 2003 | A1 |
20030105410 | Pearlman | Jun 2003 | A1 |
20030105411 | Smallwood et al. | Jun 2003 | A1 |
20030120170 | Zhu et al. | Jun 2003 | A1 |
20030120182 | Wilkinson et al. | Jun 2003 | A1 |
20030173976 | Wiegand et al. | Sep 2003 | A1 |
20030176808 | Masuo | Sep 2003 | A1 |
20030216661 | Davies | Nov 2003 | A1 |
20030216664 | Suarez | Nov 2003 | A1 |
20040015095 | Li et al. | Jan 2004 | A1 |
20040019292 | Drinan et al. | Jan 2004 | A1 |
20040059220 | Mourad et al. | Mar 2004 | A1 |
20040059242 | Masuo et al. | Mar 2004 | A1 |
20040073127 | Istvan et al. | Apr 2004 | A1 |
20040073130 | Bohm et al. | Apr 2004 | A1 |
20040077944 | Steinberg et al. | Apr 2004 | A1 |
20040116819 | Alt | Jun 2004 | A1 |
20040127793 | Mendlein et al. | Jul 2004 | A1 |
20040158167 | Smith et al. | Aug 2004 | A1 |
20040167423 | Pillon et al. | Aug 2004 | A1 |
20040171961 | Smith et al. | Sep 2004 | A1 |
20040181163 | Wong et al. | Sep 2004 | A1 |
20040181164 | Smith et al. | Sep 2004 | A1 |
20040186392 | Ward et al. | Sep 2004 | A1 |
20040210150 | Virtanen | Oct 2004 | A1 |
20040210158 | Organ et al. | Oct 2004 | A1 |
20040220632 | Burnes | Nov 2004 | A1 |
20040234113 | Miga | Nov 2004 | A1 |
20040236202 | Burton | Nov 2004 | A1 |
20040242987 | Liew et al. | Dec 2004 | A1 |
20040242989 | Zhu et al. | Dec 2004 | A1 |
20040243018 | Organ et al. | Dec 2004 | A1 |
20040252870 | Reeves et al. | Dec 2004 | A1 |
20040253652 | Davies | Dec 2004 | A1 |
20040260167 | Leonhardt | Dec 2004 | A1 |
20040267333 | Kronberg | Dec 2004 | A1 |
20040267344 | Stett et al. | Dec 2004 | A1 |
20050033281 | Bowman et al. | Feb 2005 | A1 |
20050039763 | Kraemer et al. | Feb 2005 | A1 |
20050049474 | Kellogg et al. | Mar 2005 | A1 |
20050080460 | Wang et al. | Apr 2005 | A1 |
20050085743 | Hacker et al. | Apr 2005 | A1 |
20050098343 | Fukuda | May 2005 | A1 |
20050101875 | Semler et al. | May 2005 | A1 |
20050107719 | Arad et al. | May 2005 | A1 |
20050113704 | Lawson et al. | May 2005 | A1 |
20050124908 | Belalcazar et al. | Jun 2005 | A1 |
20050137480 | Alt et al. | Jun 2005 | A1 |
20050151545 | Park et al. | Jul 2005 | A1 |
20050177061 | Alanen et al. | Aug 2005 | A1 |
20050177062 | Skrabal et al. | Aug 2005 | A1 |
20050192488 | Bryenton et al. | Sep 2005 | A1 |
20050201598 | Harel et al. | Sep 2005 | A1 |
20050203435 | Nakada | Sep 2005 | A1 |
20050203436 | Davies | Sep 2005 | A1 |
20050215918 | Frantz et al. | Sep 2005 | A1 |
20050228309 | Fisher et al. | Oct 2005 | A1 |
20050251062 | Choi et al. | Nov 2005 | A1 |
20050261743 | Kroll | Nov 2005 | A1 |
20050283091 | Kink et al. | Dec 2005 | A1 |
20060004300 | Kennedy | Jan 2006 | A1 |
20060025701 | Kasahara | Feb 2006 | A1 |
20060041280 | Stahmann et al. | Feb 2006 | A1 |
20060047189 | Takehara | Mar 2006 | A1 |
20060052678 | Drinan | Mar 2006 | A1 |
20060064029 | Arad | Mar 2006 | A1 |
20060070623 | Wilkinson et al. | Apr 2006 | A1 |
20060085048 | Cory et al. | Apr 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060100532 | Bae et al. | May 2006 | A1 |
20060111652 | McLeod | May 2006 | A1 |
20060116599 | Davis | Jun 2006 | A1 |
20060122523 | Bonmassar et al. | Jun 2006 | A1 |
20060122540 | Zhu et al. | Jun 2006 | A1 |
20060135886 | Lippert | Jun 2006 | A1 |
20060184060 | Belalcazar | Aug 2006 | A1 |
20060197509 | Kanamori et al. | Sep 2006 | A1 |
20060200033 | Keren et al. | Sep 2006 | A1 |
20060224079 | Washchuk | Oct 2006 | A1 |
20060224080 | Oku et al. | Oct 2006 | A1 |
20060241513 | Hatlestad et al. | Oct 2006 | A1 |
20060241719 | Foster et al. | Oct 2006 | A1 |
20060247543 | Cornish et al. | Nov 2006 | A1 |
20060252670 | Fiorucci et al. | Nov 2006 | A1 |
20060253016 | Baker et al. | Nov 2006 | A1 |
20060258952 | Stahmann et al. | Nov 2006 | A1 |
20060264775 | Mills et al. | Nov 2006 | A1 |
20060264776 | Stahmann et al. | Nov 2006 | A1 |
20060270942 | Mcadams | Nov 2006 | A1 |
20070007975 | Hawkins et al. | Jan 2007 | A1 |
20070010758 | Matthiessen et al. | Jan 2007 | A1 |
20070024310 | Tokuno et al. | Feb 2007 | A1 |
20070027402 | Levin et al. | Feb 2007 | A1 |
20070043303 | Osypka et al. | Feb 2007 | A1 |
20070049993 | Hofmann et al. | Mar 2007 | A1 |
20070087703 | Li et al. | Apr 2007 | A1 |
20070088227 | Nishimura | Apr 2007 | A1 |
20070106342 | Schumann | May 2007 | A1 |
20070118027 | Baker et al. | May 2007 | A1 |
20070156061 | Hess | Jul 2007 | A1 |
20070188219 | Segarra | Aug 2007 | A1 |
20070246046 | Teschner et al. | Oct 2007 | A1 |
20070270707 | Belalcazar | Nov 2007 | A1 |
20080001608 | Saulnier | Jan 2008 | A1 |
20080002873 | Reeves et al. | Jan 2008 | A1 |
20080004904 | Tran | Jan 2008 | A1 |
20080009757 | Tsoglin et al. | Jan 2008 | A1 |
20080009759 | Chetham | Jan 2008 | A1 |
20080027350 | Webler et al. | Jan 2008 | A1 |
20080039700 | Drinan et al. | Feb 2008 | A1 |
20080048786 | Feldkamp et al. | Feb 2008 | A1 |
20080051643 | Park et al. | Feb 2008 | A1 |
20080064981 | Gregory | Mar 2008 | A1 |
20080091114 | Min et al. | Apr 2008 | A1 |
20080139957 | Hubbard et al. | Jun 2008 | A1 |
20080183098 | Denison et al. | Jul 2008 | A1 |
20080188757 | Rovira et al. | Aug 2008 | A1 |
20080200802 | Bhavaraju et al. | Aug 2008 | A1 |
20080205717 | Reeves et al. | Aug 2008 | A1 |
20080221411 | Hausmann et al. | Sep 2008 | A1 |
20080247502 | Liao | Oct 2008 | A1 |
20080252304 | Woo et al. | Oct 2008 | A1 |
20080262375 | Brown et al. | Oct 2008 | A1 |
20080270051 | Essex et al. | Oct 2008 | A1 |
20080287823 | Chetham | Nov 2008 | A1 |
20080306400 | Takehara | Dec 2008 | A1 |
20080306402 | Singer | Dec 2008 | A1 |
20080319336 | Ward et al. | Dec 2008 | A1 |
20090018432 | He | Jan 2009 | A1 |
20090043222 | Chetham | Feb 2009 | A1 |
20090054952 | Glukhovsky et al. | Feb 2009 | A1 |
20090069708 | Hatlestad et al. | Mar 2009 | A1 |
20090076343 | James et al. | Mar 2009 | A1 |
20090076345 | Manicka et al. | Mar 2009 | A1 |
20090076350 | Bly et al. | Mar 2009 | A1 |
20090076410 | Libbus et al. | Mar 2009 | A1 |
20090082679 | Chetham | Mar 2009 | A1 |
20090084674 | Holzhacker et al. | Apr 2009 | A1 |
20090093730 | Grassl | Apr 2009 | A1 |
20090105555 | Dacso et al. | Apr 2009 | A1 |
20090143663 | Chetham | Jun 2009 | A1 |
20090177099 | Smith et al. | Jul 2009 | A1 |
20090209828 | Musin | Aug 2009 | A1 |
20090209872 | Pop | Aug 2009 | A1 |
20090216140 | Skrabal | Aug 2009 | A1 |
20090216148 | Freed et al. | Aug 2009 | A1 |
20090234244 | Tanaka | Sep 2009 | A1 |
20090240163 | Webler | Sep 2009 | A1 |
20090264727 | Markowitz | Oct 2009 | A1 |
20090264745 | Markowitz et al. | Oct 2009 | A1 |
20090264776 | Vardy | Oct 2009 | A1 |
20090264791 | Gregory et al. | Oct 2009 | A1 |
20090275854 | Zielinski et al. | Nov 2009 | A1 |
20090275855 | Zielinski et al. | Nov 2009 | A1 |
20090287102 | Ward | Nov 2009 | A1 |
20090306535 | Davies et al. | Dec 2009 | A1 |
20090318778 | Dacso et al. | Dec 2009 | A1 |
20090326408 | Moon | Dec 2009 | A1 |
20100007357 | Spielberger et al. | Jan 2010 | A1 |
20100049077 | Sadleir et al. | Feb 2010 | A1 |
20100056881 | Libbus et al. | Mar 2010 | A1 |
20100094160 | Eror et al. | Apr 2010 | A1 |
20100100003 | Chetham et al. | Apr 2010 | A1 |
20100100146 | Blomqvist | Apr 2010 | A1 |
20100106046 | Shochat et al. | Apr 2010 | A1 |
20100152605 | Ward | Jun 2010 | A1 |
20100168530 | Chetham et al. | Jul 2010 | A1 |
20100191141 | Aberg | Jul 2010 | A1 |
20100228143 | Teschner et al. | Sep 2010 | A1 |
20110025348 | Chetham et al. | Feb 2011 | A1 |
20110034806 | Hartov et al. | Feb 2011 | A1 |
20110046505 | Cornish et al. | Feb 2011 | A1 |
20110054343 | Chetham et al. | Mar 2011 | A1 |
20110054344 | Slizynski | Mar 2011 | A1 |
20110060239 | Gaw | Mar 2011 | A1 |
20110060241 | Martinsen et al. | Mar 2011 | A1 |
20110082383 | Cory et al. | Apr 2011 | A1 |
20110087129 | Chetham et al. | Apr 2011 | A1 |
20110118619 | Burton et al. | May 2011 | A1 |
20110190655 | Moissl et al. | Aug 2011 | A1 |
20110208084 | Martinez et al. | Aug 2011 | A1 |
20110230784 | Slizynski et al. | Sep 2011 | A2 |
20110245712 | Patterson et al. | Oct 2011 | A1 |
20110251513 | Chetham et al. | Oct 2011 | A1 |
20110274327 | Wehnes et al. | Nov 2011 | A1 |
20110282180 | Goldkuhl et al. | Nov 2011 | A1 |
20120071772 | Chetham | Mar 2012 | A1 |
20120165884 | Xi | Jun 2012 | A1 |
20120238896 | Garber et al. | Sep 2012 | A1 |
20130102873 | Hamaguchi | Apr 2013 | A1 |
20130165760 | Erlinger et al. | Jun 2013 | A1 |
20130165761 | De Limon et al. | Jun 2013 | A1 |
20140148721 | Erlinger et al. | May 2014 | A1 |
20140371566 | Raymond et al. | Dec 2014 | A1 |
Number | Date | Country |
---|---|---|
2231038 | Nov 1999 | CA |
2638958 | Jun 2000 | CA |
2613524 | Jan 2007 | CA |
2615845 | Jan 2007 | CA |
1236597 | Dec 1999 | CN |
1329875 | Jan 2002 | CN |
0357309 | Mar 1990 | EP |
377887 | Jul 1990 | EP |
581073 | Feb 1994 | EP |
339471 | Mar 1997 | EP |
865763 | Sep 1998 | EP |
0869360 | Oct 1998 | EP |
1078597 | Feb 2001 | EP |
1080686 | Mar 2001 | EP |
1112715 | Apr 2001 | EP |
1112715 | Jul 2001 | EP |
1146344 | Oct 2001 | EP |
1114610 | Nov 2001 | EP |
1177760 | Feb 2002 | EP |
1219937 | Jul 2002 | EP |
1238630 | Sep 2002 | EP |
1247487 | Oct 2002 | EP |
1329190 | Jul 2003 | EP |
1338246 | Aug 2003 | EP |
1080686 | Mar 2004 | EP |
1452131 | Sep 2004 | EP |
1553871 | Jul 2005 | EP |
1118308 | Nov 2005 | EP |
1629772 | Mar 2006 | EP |
1247487 | Jan 2008 | EP |
1903938 | Apr 2008 | EP |
1909642 | Apr 2008 | EP |
1948017 | Jul 2008 | EP |
1353595 | Aug 2008 | EP |
2748928 | Nov 1997 | FR |
1441622 | Jul 1976 | GB |
2131558 | Jun 1984 | GB |
2260416 | Apr 1993 | GB |
2426824 | Dec 2006 | GB |
6-74103 | Oct 1994 | JP |
8191808 | Jul 1996 | JP |
10225521 | Aug 1998 | JP |
2000107138 | Apr 2000 | JP |
2001037735 | Feb 2001 | JP |
2001061804 | Mar 2001 | JP |
2001-204707 | Jul 2001 | JP |
2001224568 | Aug 2001 | JP |
2001-245866 | Sep 2001 | JP |
2002502274 | Jan 2002 | JP |
2002238870 | Aug 2002 | JP |
2002350477 | Dec 2002 | JP |
2003-502092 | Jan 2003 | JP |
2003075487 | Mar 2003 | JP |
2003-116803 | Apr 2003 | JP |
2003116805 | Apr 2003 | JP |
2003230547 | Aug 2003 | JP |
200461251 | Feb 2004 | JP |
2006-501892 | Jan 2006 | JP |
2008-502382 | Jan 2008 | JP |
2010-526604 | Aug 2010 | JP |
2112416 | Jun 1998 | RU |
WO 88-07392 | Oct 1988 | WO |
WO 91-19454 | Dec 1991 | WO |
WO 93-18821 | Sep 1993 | WO |
WO 9401040 | Jan 1994 | WO |
WO 94-10922 | May 1994 | WO |
WO 96-01586 | Jan 1996 | WO |
WO 96-12439 | May 1996 | WO |
WO 96-32652 | Oct 1996 | WO |
WO 97-11638 | Apr 1997 | WO |
WO 97-14358 | Apr 1997 | WO |
WO 97-24156 | Jul 1997 | WO |
WO 98-06328 | Feb 1998 | WO |
WO 9812983 | Apr 1998 | WO |
WO 98-23204 | Jun 1998 | WO |
WO 98-33553 | Aug 1998 | WO |
WO 98-51211 | Nov 1998 | WO |
WO 99-42034 | Aug 1999 | WO |
WO 99-48422 | Sep 1999 | WO |
WO 00-19886 | Apr 2000 | WO |
WO 00-40955 | Jul 2000 | WO |
WO 00-78213 | Dec 2000 | WO |
WO 00-79255 | Dec 2000 | WO |
WO 01-27605 | Apr 2001 | WO |
WO 01-50954 | Jul 2001 | WO |
WO 01-52733 | Jul 2001 | WO |
WO 0167098 | Sep 2001 | WO |
WO 02-053028 | Jul 2002 | WO |
WO 02-062214 | Aug 2002 | WO |
WO 02-094096 | Nov 2002 | WO |
WO 2004-000115 | Dec 2003 | WO |
WO 2004002301 | Jan 2004 | WO |
WO 2004006660 | Jan 2004 | WO |
WO 2004-021880 | Mar 2004 | WO |
WO 2004-026136 | Apr 2004 | WO |
WO 2004-030535 | Apr 2004 | WO |
WO 2004-032738 | Apr 2004 | WO |
WO 2004-043252 | May 2004 | WO |
WO 2004-047635 | Jun 2004 | WO |
WO 2004-047636 | Jun 2004 | WO |
WO 2004-047638 | Jun 2004 | WO |
WO 2004-049936 | Jun 2004 | WO |
WO 2004-083804 | Sep 2004 | WO |
WO 2004-084087 | Sep 2004 | WO |
WO 2004-084723 | Oct 2004 | WO |
WO 2004-098389 | Nov 2004 | WO |
WO 2004112563 | Dec 2004 | WO |
WO 2005-010640 | Feb 2005 | WO |
WO 2005-018432 | Mar 2005 | WO |
WO 2005-027717 | Mar 2005 | WO |
WO 2005-051163 | Jun 2005 | WO |
WO 2005-051194 | Jun 2005 | WO |
WO 2005-122881 | Dec 2005 | WO |
WO 2005-122888 | Dec 2005 | WO |
WO 2006-045051 | Apr 2006 | WO |
WO 2006-056074 | Jun 2006 | WO |
WO 2006-129108 | Dec 2006 | WO |
WO 2006-129116 | Dec 2006 | WO |
WO 2007-002991 | Jan 2007 | WO |
WO 2007-002992 | Jan 2007 | WO |
WO 2007-002993 | Jan 2007 | WO |
WO 2007-009183 | Jan 2007 | WO |
WO 2007045006 | Apr 2007 | WO |
WO 2007041783 | Apr 2007 | WO |
WO 2007-056493 | May 2007 | WO |
WO 2007-070997 | Jun 2007 | WO |
WO 2007105996 | Sep 2007 | WO |
WO 2007-128952 | Nov 2007 | WO |
WO 2008-011716 | Jan 2008 | WO |
WO 2008-054426 | Aug 2008 | WO |
WO 2008119166 | Oct 2008 | WO |
WO 2008-119166 | Oct 2008 | WO |
WO 2008-138062 | Nov 2008 | WO |
WO 2008149125 | Dec 2008 | WO |
WO 2009-018620 | Feb 2009 | WO |
WO 2009-027812 | Mar 2009 | WO |
WO 2009-036369 | Mar 2009 | WO |
WO 2009-068961 | Jun 2009 | WO |
WO 2009100491 | Aug 2009 | WO |
WO 2009-112965 | Sep 2009 | WO |
WO 2010-003162 | Jan 2010 | WO |
WO 2010-029465 | Mar 2010 | WO |
WO 2010-069023 | Jun 2010 | WO |
WO 2010-076719 | Jul 2010 | WO |
WO 2011-018744 | Feb 2011 | WO |
WO 2011-022068 | Feb 2011 | WO |
WO 2011-050393 | May 2011 | WO |
WO 2011-075769 | Jun 2011 | WO |
WO 2011-113169 | Sep 2011 | WO |
WO 2011-136867 | Nov 2011 | WO |
WO 2014-176420 | Oct 2014 | WO |
Entry |
---|
Ivorra, Antoni, et al., “Bioimpedance dispersion width as a parameter to monitor living tissues,” Physiol. Meas. 26 (2005) S165-S173. |
Locus, www.dictionary.com, printed Nov. 21, 2016 (6 pages). |
Cornish, et al., “Optimizing Electrode Sites for Segmental Bioimpedance Measurements” Physiological Measurement, Institute of Physics, 1999, pp. 241-250, vol. 20, No. 3. |
Cornish, et al., “A New Technique for the Quantification of Peripheral Edema with Application in Both Unilateral and Bilateral Cases” Angiology, 2002, pp. 41-47, vol. 53, No. 1. |
Fenech, et al., “Extracellular and Intracellular Volume Variations During Postural Change Measured by Segmental and Wrist-Ankle Bioimpedance Spectroscopy” IEEE Transactions on Biomedical Engineering, IEEE Service Center, 2004, pp. 166-175, vol. 51, No. 1. |
Golden, et al., “Assessment of Peripheral Hemodynmics using Impedance Plethysmogrphy” Physical Therapy, 1986, pp. 1544-1547, vol. 66, No. 10. |
Kim, et al., “Impedance Tomography and its Application in Deep Venous Thrombosis Detection” IEEE Engineering in Medicine and Biology Magazine, IEEE Service Center, 1989, pp. 46-49, vol. 8, No. 1. |
Nawarycz, et al., “triple-frequency Electroimpedance Method for Evaluation of Body Water Compartments” Medical & Biological Engineering & Computing, 1996, pp. 181-182, vol. 34, No. Supp. 01, Pt. 02. |
Noshiro, et al., “Electrical Impedance in the Lower Limbs of Patients with Duchenne Muscular Dystrophy: A Preliminary Study” Medical & Biological Engineering & Computing, 1993, pp. 97-102, vol. 31, No. 2. |
Seo, et al., “Measuring Lower Leg Swelling: Optimum Frequency for Impedance Method” Medical &, Biological Engineering & Computing, 2001, pp. 185-189, vol. 39. |
Seoane, et al., “Current Source for Wideband Electrical Bioimpedance Spectroscopy Based on a Single Operational Amplifier” World Congress on Medical Physics and Biomedical Engineering 2006, pp. 707-710, vol. 14. |
Smith, et al., “A Pilot Study for Tissue Characterization Using Bio-impedance Mapping” 13th International Conference on Electrical Bio-impedance and the 8th Conference on Electrical Impedance Tomography 2007, pp. 146-149. |
Stanton, et al., “Non-invasive Assessment of the Lymphedematous Limb” The International Society of Lymphology, 2000, pp. 122-135, vol. 33, No. 3. |
Abdullah M. Z.; Simulation of an inverse problem in electrical impedance tomography using resistance electrical network analogues; International Journal of Electrical Engineering Education; vol. 36, No. 4, pp. 311-324; Oct. 1999. |
Al-Hatib, F.; Patient Instrument connection errors in bioelectrical impedance measurement; Physiological Measurement; vol. 19, No. 2, pp. 285-296; May 2, 1998. |
Bella, et al., Relations of Left Ventricular Mass to Fat-Free and Adipose Body Mass: The Strong Heart Study, (1998) Circulation, vol. 98, pp. 2538-2544. |
Boulier, A. et al.; Fat-Free Mass Estimation by Two Electrode Impedance Method; American Journal of Clinical Nutrition; vol. 52, pp. 581-585; 1990. |
Bracco, D. et al., Bedside determination of fluid accumulation after cardiac surgery using segmental bioelectrical impedance, Critical Care Medicine, vol. 26, No. 6, pp. 1065-1070, 1998. |
Chaudary, S.S. et al.; Dielectric Properties of Normal & Malignant Human Breast Tissues at Radiowave and Microwave Frequencies; Indian Journal of Biochemistry & Biophysics; vol. 21, No. 1, pp. 76-79; 1984. |
Cornish, B.H. et al.; Alteration of the extracellular and total body water volumes measured by multiple frequency bioelectrical impedance analysis; Nutrition Research; vol. 14, No. 5, pp. 717-727; 1994. |
Cornish, B.H. et al.; Bioelectrical impedance for monitoring the efficacy of lymphoedema treatment programmes; Breast Cancer Research and Treatment; vol. 38, pp. 169-176; 1996. |
Cornish, B.H. et al.; Data analysis in multiple-frequency bioelectrical impedance analysis; Physiological Measurement; vol. 19, No. 2, pp. 275-283; May 1, 1998. |
Cornish, B.H. et al.; Early diagnosis of lymphedema using multiple frequency bioimpedance; Lymphology; vol. 34, pp. 2-11; Mar. 2001. |
Cornish, B.H. et al.; Early diagnosis of lymphoedema in postsurgery breast cancer patients; Annals New York Academy of Sciences; pp. 571-575; May 2000. |
Cornish, B.H. et al.; Quantification of Lymphoedema using Multi-frequency Bioimpedance; Applied Radiation and Isotopes; vol. 49, No. 5/6, pp. 651-652; 1998. |
De Luca, F. et al., Use of low-frequency electrical impedance measurements to determine phospoholipid content in amniotic fluid; Physics in Medicine and Biology, vol. 41, pp. 1863-1869, 1996. |
Deurenberg, P. et al., Multi-frequency bioelectrical impedance: a comparison between the Cole-Cole modelling and Hanai equations with the classically impedance index approach, Annals of Human Biology, vol. 23, No. 1, pp. 31-40, 1996. |
Dines K.A. et al.; Analysis of electrical conductivity imaging; Geophysics; vol. 46, No. 7, pp. 1025-1036; Jul. 1981. |
Ellis, K.J. et al; Human hydrometry: comparison of multifrequency bioelectrical impedance with 2H2O and bromine dilution; Journal of Applied Physiology; vol. 85, No. 3, pp. 1056-1062; 1998. |
Ezenwa, B.N. et al.; Multiple Frequency System for Body Composition Measurement; Proceedings of the Annual International Conference of the Engineering in Medicine and Biology Society; vol. 15; pp. 1020-1021; 1993. |
Forslund, A.H. et al.; Evaluation of modified multicompartment models to calculate body composition in healthy males; American Journal of Clinical Nutrition; vol. 63, pp. 856-862; 1996. |
Gersing, E.; Impedance spectroscopy on living tissue for determination of the state of Organs; Bioelectrochemistry and Bioenergetics; vol. 45, pp. 145-149; 1998. |
Gerth, W.A. et al.; A computer-based bioelectrical impedance spectroscopic system for noninvasive assessment of compartmental fluid redistribution; Third Annual IEEE Symposium on Computer Based Medical Systems, Jun. 3-6, 1990, University of NC. At Chapel Hill; pp. 446-453; Jun. 1990. |
Gudivaka R. et al; Single- and multifrequency models for bioelectrical impedance analysis of body water compartments; Applied Physiology; vol. 87, Issue 3, pp. 1087-1096; 1999. |
Iacobellis, G., et al. Influence of Excess Fat on Cardiac Morphology and Function: Study in Uncomplicated Obesity, (2002) Obesity Research, vol. 10, pp. 767-773. |
Jones, C.H. et al; Extracellular fluid volume determined by bioelectric impedance and serum albumin in CAPD patients; Nephrology Dialysis Transplantation; vol. 13, pp. 393-397; 1998. |
Jossinet, J. et al.; A Study for Breast Imaging with a Circular Array of Impedance Electrodes; Proc. Vth Int. Conf. Bioelectrical Impedance, 1981, Tokyo, Japan; pp. 83-86; 1981. |
Jossinet, J. et al.; Technical Implementation and Evaluation of a Bioelectrical Breast Scanner; Proc. 10.sup.th Int. Conf. IEEE Engng. Med. Biol., 1988, New Orleans, USA (Imped. Imaging II); vol. 1.p. 289; 1988. |
Kanai, H. et al.; Electrical Measurement of Fluid Distribution in Legs and Arms; Medical Progress through technology; pp. 159-170; 1987. |
Karason, K., et al., Impact of Blood Pressure and Insulin on the Relationship Between Body Fat and Left Ventricular Structure, (2003) European Heart Journal, vol. 24, pp. 1500-1505. |
Liu R. et al; Primary Multi-frequency Data Analyze in Electrical Impedance Scanning; Proceedings of the IEEE-EMBS 2005, 27th Annual International Conference of the Engineering in Medicine and Biology Society, Shanghai, China; pp. 1504-1507; , Sep. 1-4, 2005. |
Lozano, A. et al.; Two-frequency impedance plethysmograph: real and imaginary parts; Medical & Biological Engineering & Computing; vol. 28, No. 1, pp. 38-42; Jan. 1990. |
Lukaski, H.C. et al.; Estimation of Body Fluid Volumes Using Tetrapolar Bioelectrical Impedance Measurements; Aviation, Space, and Environmental Medicine; pp. 1163-1169; Dec. 1988. |
Man, B. et al. Results of Preclinical Tests for Breast Cancer Detection by Dielectric Measurements; XII Int. Conf. Med. Biol. Engng. 1979, Jerusalem, Israel. Springer Int., Berlin; Section 30.4; 1980. |
Mattar, J.A., Application of Total Body Impedance to the Critically Ill Patient, New Horizons, vol. 4, No. 4, pp. 493-503, Nov. 1996. |
McCullah, et al.; Bioelectrical Impedance Analysis Measures the Ejection Fraction of the Calf Muscle Pump; IFMBE Proceedings; vol. 17, pp. 616-619; 2007. |
McDougal D., et al.; Body Composition Measurements From Whole Body Resistance and Reactance; Surgical Forum; vol. 36, pp. 43-44; 1986. |
Osterman K.S. et al.; Multifrequency electrical impedance imaging: preliminary in vivo experience in breast; Physiological Measurement; vol. 21, No. 1, pp. 99-109; Feb. 2000. |
Ott, M. et al.; Bioelectrical Impedance Analysis as a Predictor of Survival in Patients with Human Immunodeficiency Virus Infection; Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology; vol. 9, pp. 20-25; 1995. |
Pethig, R. et al.; The Passive Electrical Properties of Biological Systems: Their Significance in Physiology, Biophysics and Biotechnology; Physics in Medicine and Biology; vol. 32, pp. 933-970; 1987. |
Piperno, G. et al.; Breast Cancer Screening by Impedance Measurements; Frontiers of Medical & Biological Engineering; vol. 2, pp. 111-117; 1990. |
Rigaud, B. et al.; Bioelectrical Impedance Techniques in Medicine; Critical Reviews in Biomedical Engineering; vol. 24 (4-6), pp. 257-351; 1996. |
Scharfetter, H. et al.; Effect of Postural Changes on the Reliability of Volume Estimations from Bioimpedance Spectroscopy Data; Kidney International; vol. 51, No. 4, pp. 1078-2087; 1997. |
Schneider, I.; Broadband signals for electrical impedance measurements for long bone fractures; Engineering in Medicine and Biology Society, 1996. Bridging Disciplines for Biomedicine. Proceedings of the 18th Annual International Conference of the IEEE; vol. 5, pp. 1934-1935; Oct. 31, 1996. |
Skidmore, R. et al.; A Data Collection System for Gathering Electrical Impedance Measurements from the Human Breast; Clinical Physics Physiological Measurement; vol. 8, pp. 99-102; 1987. |
Sollish, B.D. et al.; Microprocessor-assisted Screening Techniques; Israel Journal of Medical Sciences; vol. 17, pp. 859-864; 1981. |
Steijaert, M. et al.; The use of multi-frequency impedance to determine total body water and extracellular water in obese and lean female individuals; International Journal of Obesity; vol. 21, pp. 930-934; 1997. |
Surowiec, A.J. et al.; Dielectric Properties of Brest Carcinoma and the Surrounding Tissues; IEEE Transactions on Biomedical Engineering; vol. 35, pp. 257-263; 1988. |
Tedner, B.; Equipment Using Impedance Technique for Automatic Recording of Fluid-Volume Changes During Haemodialysis; Medical & Biological Engineering & Computing; pp. 285-290; 1983. |
Thomas. B.J. et al.; Bioelectrical impedance analysis for measurement of body fluid volumes—A review; Journal of Clinical Engineering; vol. 17, No. 16, pp. 505-510; 1992. |
Thomas. B.J. et al.; Bioimpedance Spectrometry in Determination of Body Water Compartments: Accuracy and Clinical Significance; Applied Radiation and Isotopes; vol. 49, No. 5/6, pp. 447-455; 1998. |
Thomas. B.J.; Future Technologies; Asia Pacific Journal Clinical Nutrition; vol. 4, pp. 157-159; 1995. |
Ulgen, Y. et al.; Electrical parameters of human blood; Engineering in Medicine and Biology Society, 1998. Proceedings of the 20th Annual International Conference of the IEEE; vol. 6, pp. 2983-2986; Nov. 1, 1998. |
Ward, L.C. et al., Multi-frequency bioelectrical impedance augments the diagnosis and management of lymphoedema in post-mastectomy patients, European Journal of Clinical Investigation, vol. 22, pp. 751-754, 1992. |
Ward, L.C. et al.; Determination of Cole parameters in multiple frequency bioelectrical impedance analysis using only the measurement of impedances; Four-frequency fitting; Physiological Measurement; vol. 27, No. 9, pp. 839-850; Sep. 2006. |
Ward, L.C. et al.; There is a better way to measure Lymphoedema; National Lymphedema Network Newsletter; vol. 7, No. 4, pp. 89-92; Oct. 1995. |
Woodrow, G. et al; Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis; Nephrology Dialysis Transplantation; vol. 15, pp. 862-866; 2000. |
Yamakoshi, K.; Non-Invasive Cardiovascular Hemodynamic Measurements; Sensors in Medicine and Health Care; pp. 107-160; 2004. |
Yoshinaga, M., Effect of Total Adipose Weight and Systemic Hypertension on Left Ventricular Mass in Children, American Journal of Cardiology, (1995) vol. 76, pp. 785-787. |
Blad et al.; Impedance Spectra of Tumour Tissue in Tomparison with Normal Tissue; A Possible Clinical Application for Electrical Impedance Tomography; Physiological Measurement; vol. 17, pp. A105-A115; 1996. |
De Lorenzo et al.; Determination of Intracellular Water by Multifrequency Bioelectrical Impedance; Ann. Nutr. Metab.; vol. 39, pp. 177-184; 1995. |
Edwards, L.S.; A Modified Pseudosection for Resistivity and IP; Geophysics; vol. 42, No. 5, pp. 1020-1036; 1977. |
Hansen, E.; On the Influence of Shape and Variations in Conductivity of the Sample on Four-Point Measurements; Applied Scientific Research; Section B; vol. 8, Issue 1, pp. 93-104 1960. |
Igel, J.; On the Small-Scale Variability of Electrical Soil Properties and Its Influence on Geophysical Measurements; Ph.D. Thesis; Frankfurt University; Hanover, Germany; p. 188; 2007. |
Kyle et al.; Bioelectrical Impedance Analysis—Part I: Review of Principles and Methods; Clinical Nutrition; vol. 23, pp. 1226-1243; 2004. |
Loke et al.; Least Squares Deconvolution of Apparent Resistivity Pseudosections; Geophysics; vol. 60, No. 6, pp. 1682-1690; 1995. |
McAdams et al; Tissue Impedance: a Historical Overview Physiological Measurement; Institute of Physics Publishing; vol. 16. (3A), pp. A1-A13; 1995. |
McEwan et al.; Battery Powered and Wireless Electrical Impedance Tomography Spectroscopy Imaging Ssing Bluetooth; Medicon IFMBE Proceedings; vol. 16, pp. 798-801; 2007. |
Roy, A.; Depth of investigation in Direct Current Methods Geophysics; vol. 36, pp. 943-959; 1971. |
Wilson et al.; Feasibility Studies of Electrical Impedance Spectroscopy for Monitoring Tissue Response to Photodynamic Therapy; Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII; Proc. SPIE 3247; pp. 69-80; 1998. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2009/000163 dated Apr. 16, 2009. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2006/000922 dated Oct. 13, 2006. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2006/001057 dated Oct. 25, 2006. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2008/000034 dated Mar. 17, 2008. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/CA2008/000588 dated Aug. 13, 2008. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2006/000924 dated Oct. 5, 2006. |
International Search Report and Written Opinion of the International Searching Authority issued in PCT/AU2008/001521 dated Jan. 15, 2009. |
Number | Date | Country | |
---|---|---|---|
20130131538 A1 | May 2013 | US |